.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Farmers Insurance
US Department of Justice
Deloitte
Dow
Cerilliant
Queensland Health
Medtronic
Boehringer Ingelheim

Generated: December 13, 2017

DrugPatentWatch Database Preview

PRANDIN Drug Profile

« Back to Dashboard

Which patents cover Prandin, and when can generic versions of Prandin launch?

Prandin is a drug marketed by Gemini Labs Llc and is included in one NDA.

The generic ingredient in PRANDIN is repaglinide. There are sixteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the repaglinide profile page.
Drug patent expirations by year for PRANDIN

Pharmacology for PRANDIN

Drug ClassGlinide
Mechanism of ActionPotassium Channel Antagonists

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-001Dec 22, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-002Dec 22, 1997ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-003Dec 22, 1997ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PRANDIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-002Dec 22, 1997► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-003Dec 22, 1997► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-003Dec 22, 1997► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-001Dec 22, 1997► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-002Dec 22, 1997► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-003Dec 22, 1997► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-002Dec 22, 1997► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-002Dec 22, 1997► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-001Dec 22, 1997► Subscribe► Subscribe
Gemini Labs LlcPRANDINrepaglinideTABLET;ORAL020741-002Dec 22, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for PRANDIN

Drugname Dosage Strength RLD Submissiondate
repaglinideTablets0.5 mg, 1 mg and 2 mgPrandin2/10/2005

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Fish and Richardson
Boehringer Ingelheim
US Department of Justice
Colorcon
Harvard Business School
Deloitte
Covington
UBS
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot